Anticardiolipin (acl) antibodies and lupus anticoagulant
|
|
- Berniece Baldwin
- 5 years ago
- Views:
Transcription
1 Anticardiolipin Antibodies and Recurrent Coronary Events A Prospective Study of 1150 Patients Androniki Bili, MD; Arthur J. Moss, MD; Charles W. Francis, MD; Wojciech Zareba, MD, PhD; Luc F. Miller Watelet, PhD; Ignacio Sanz, MD; for the Thrombogenic Factors and Recurrent Coronary Events Investigators* Background The association of anticardiolipin (acl) antibodies with coronary artery disease has been shown in several studies but remains controversial. We evaluated the association of acl and anti 2 -glycoprotein I (a 2 GPI) antibodies with the risk of recurrent cardiac events in postinfarction patients. Methods and Results The study population consisted of 1150 patients with acute myocardial infarction. Levels of IgG and IgM acl and a 2 GPI antibodies were determined on sera collected before hospital discharge. There were 131 recurrent cardiac events (nonfatal myocardial infarctions or cardiac deaths) over a mean follow-up period of 24.6 months. Patients with elevated IgG acl antibodies had a higher event rate than patients with low levels (P 0.05). Multivariate Cox analysis after adjustment for relevant clinical covariates showed that elevated levels of IgG acl (hazard ratio 1.63; P 0.01) and low levels of IgM acl (hazard ratio of 1.76; P 0.02) antibodies contribute independent risks for recurrent cardiac events. Patients with elevated IgG acl and low IgM acl antibody levels had a 3-fold higher risk of recurrent cardiac events than patients with low IgG acl and elevated IgM acl antibody levels (P 0.001). There was no significant association of the a 2 GPI antibodies with recurrent cardiac events. Conclusions In postinfarction patients, elevated IgG acl and low IgM acl antibodies are independent risk factors for recurrent cardiac events. Patients with both elevated IgG acl and low IgM acl antibodies have the highest risk. These findings shed additional light on the mechanistic role of acl antibodies in coronary artery disease in patients without autoimmune diseases. (Circulation. 2000;102: ) Key Words: antibodies thrombosis coronary disease myocardial infarction Anticardiolipin (acl) antibodies and lupus anticoagulant are the main antibodies associated with the antiphospholipid syndrome, which manifests clinically as vascular thrombosis and pregnancy morbidity. 1 acl antibodies are strongly associated with venous and arterial thrombosis, both in patients with systemic lupus erythematosus (SLE) and in patients without any apparent autoimmune diseases. 2,3 It is known that acl antibodies require a serum cofactor, 2 -glycoprotein I ( 2 GPI) or apolipoprotein H, for binding to cardiolipin in vitro. 4 Antibodies to 2 GPI can be measured directly and were shown to be more specific than acl antibodies for the clinical manifestations of antiphospholipid syndrome. 5 7 However, these are mostly retrospective studies and mainly involve patients with SLE. An association of acl antibodies with coronary artery disease has been shown in several 8 13 but not all studies. 14,15 In the present study, we evaluated the association of acl and anti 2 -GPI (a 2 GPI) antibodies with recurrent myocardial infarction (MI) or cardiac death in a large cohort of patients without autoimmune diseases. The patients were participants in the Thrombogenic Factors and Recurrent Coronary Events (Thrombo) study, a multicenter prospective cohort study that examined the risk of different thrombogenic factors for recurrent coronary events. 16 Methods Patients The Thrombo study recruited 1161 patients hospitalized for acute MI (index MI). Serum samples were collected before hospital discharge and at 2 months after the acute event. We conducted our study on the predischarge sera (average time from index MI to discharge 10.9 days, with range of 1 to 31 days). The study included men or women 21 years of age with enzyme confirmation of the index MI with symptoms and/or ECG changes consistent with an acute MI. The index MI could be Q-wave or non Q-wave in type and either a first or a recurrent infarction. Exclusion criteria were coronary artery bypass grafting surgery during the hospital phase of the index MI, malignancy, or severe hepatic, renal, or cerebral disease. 16 Received January 4, 2000; revision received April 6, 2000; accepted April 7, From the Allergy, Immunology, and Rheumatology Unit (A.B., I.S.), the Cardiology Unit (A.J.M., W.Z.), and the Vascular Medicine Unit (C.W.F.) of the Department of Medicine and the Department of Biostatistics (L.F.M.W.), University of Rochester Medical Center, Rochester, NY. *The Thrombo Investigators are listed in Reference 16. Correspondence to Arthur J. Moss, MD, University of Rochester Medical Center, 601 Elmwood Ave, BOX 653, Rochester, NY heartajm@heart.rochester.edu 2000 American Heart Association, Inc. Circulation is available at
2 Bili et al Anticardiolipin Antibodies and Coronary Events 1259 TABLE 1. Baseline Patient Characteristics According to acl Antibody Type and Quartile Level acl Antibody IgG acl Antibody IgM Characteristic All Patients (n 1150) Q 4 (n 288) Q 1 3 (n 862) Q 4 (n 257) Q 1 3 (n 893) Age 60 y Male sex Nonwhite race 26 35* 23 19* 28 History Prior MI Treated hypertension Diabetes mellitus Stroke Cigarette smoking status Never smoked Ex-smoker Current smoker Index MI New Q wave Pulmonary congestion Ejection fraction Medications at enrollment Acetylsalicylic acid ACE inhibitors Blockers Calcium-channel blockers Diuretics Oral anticoagulants Lipid-lowering agents acl antibodies IgG, GPL IgM, MPL Antibodies to 2 GPI IgG, SGU IgM, SMU Q 4 indicates highest quartile; Q 1 3, lower 3 quartiles. Values are percentage; plus-minus values are mean SD. *P 0.01 between highest quartile and lower 3 quartiles. Dicumarol or warfarin. Includes statin-type medications. Study Protocol Baseline demographic data regarding known risk factors for coronary artery disease and recurrent MI were collected in all patients. The patients were followed up by phone and with regular clinic visits. Eighteen patients were lost to follow-up, and they were included in the analysis up to the time of their last contact. The human investigation committees of all the participating hospitals approved the study protocol. Written informed consent was obtained from all study participants. Measurement of Antibodies All the tests were done in duplicate with sera stored at 70 C, and the mean value was obtained. One of the authors performed all the tests in the same laboratory environment. Determination of acl antibodies was performed by standardized ELISA for both IgG and IgM isotypes (REAADS Medical Products, Inc) with bovine calf serum in the sample diluent as the source of 2 GPI. Results are expressed as GPL units for the IgG (positive 23 GPL) and MPL units for the IgM (positive 11 MPL) acl antibodies, with 1 GPL or MPL unit being equivalent to 1 g/ml of an affinity-purified standard IgG or IgM acl antibody sample. 17 Determination of IgM and IgG a 2 GPI antibodies was performed by ELISA with irradiated and chemically activated plastic microwell plates containing purified human 2 GPI (INOVA, Inc). Results are expressed in standardized units, 18 SGU for the IgG (positive 20 SGU) and SMU for the IgM (positive 20 SMU) a 2 GPI antibodies. All tests met the quality control standards as determined by the manufacturer. Statistical Analysis The end points were cardiac mortality and cardiac morbidity with rehospitalization as the result of recurrent nonfatal MI (cardiac
3 1260 Circulation September 12, 2000 events). The same diagnostic criteria as for the index MI were used for the recurrent nonfatal MI. The first recurrent cardiac event (cardiac death or recurrent nonfatal MI) that occurred was used as the end point for each patient. The baseline characteristics of patients with versus patients without cardiac events were compared by 2 test. Univariate analysis of the IgG and IgM acl and a 2 GPI antibodies in relation to the outcome was performed by Wilcoxon s rank-sum test and 2 test where appropriate. For the survival analyses, the IgG and IgM acl and IgM a 2 GPI antibodies were dichotomized at a cutoff point closest to the 75th percentile, and comparisons of the highest quartile (Q 4 ) versus the lower 3 quartiles (Q 1 3 ) were performed. This dichotomization parallels the analysis of the original Thrombo study and resolves the problem of skewness. The cutoff values for the highest quartile were 12.5 GPL for IgG acl, 4.1 MPL for IgM acl, and 2.0 SMU for IgM a 2 GPI antibodies. For IgG a 2 GPI antibodies, values of the 95th percentile were used for analysis rather than the quartile approach because there were only 47 patients with any detectable level of these antibodies. Kaplan-Meier survival analysis was used for estimation of event rates in association with the IgG and IgM acl and a 2 GPI antibodies. The Cox proportional-hazards survivorship model was used to evaluate the independent contribution of risk variables to outcome events. In the construction of the Cox model, a clinical model was first obtained by including any clinical variable that entered the model at a level of significance 0.1 after a forward stepwise regression scheme. This approach was used to ensure inclusion of any added contribution to this model from important covariates with borderline levels of significance. Individual medications (as listed in Table 1) were tested in the model one at a time. The SAS statistical program (SAS Institute, Inc) was used for data analysis. Results Of the 1161 patients recruited, serum samples were available for testing on The baseline characteristics for the entire study population and for patients in the highest and lower 3 IgG and IgM acl antibody quartiles are shown in Table 1. Race was the only covariate with significantly different frequencies in the high and low quartile distributions of both IgG and IgM acl antibodies. During the mean follow-up period of 24.6 months (range 0 to 42 months), a total of 131 recurrent cardiac events (84 cardiac deaths and 47 nonfatal MI) occurred. The group with events was older, with a higher percentage having had a prior MI before the index MI and having hypertension, diabetes mellitus, pulmonary congestion, and ejection fraction 30%. The mean levels and number of patients in the highest quartiles of IgG and IgM acl and a 2 GPI antibodies in those with and without coronary events are shown in Table 2. There is a trend for higher IgG acl and lower IgM acl antibody levels in patients with than without events (P 0.06 for both). The highest quartiles of IgG acl and IgM acl antibodies show a similar trend (Table 2). The IgG and IgM a 2 GPI antibodies did not show a significant association or a meaningful trend with recurrent cardiac events. Kaplan-Meier survivorship analysis for the IgG and IgM acl antibodies is shown in the Figure. Patients in the highest quartile of IgG acl antibodies had a higher coronary event rate than patients in the lower 3 quartiles (P 0.05). A reverse trend was observed for the IgM acl antibodies (P 0.06). The risk contributed by acl antibodies to the Cox model after adjustment for relevant clinical covariates is shown in Table 3. The variables that entered the clinical model at the 0.1 level of significance were age 60 years, prior MI before TABLE 2. Distribution of acl and a 2 GPI Antibodies in Patients With and Without Recurrent Coronary Events Antibodies Patients With Events (n 131) Patients Without Events (n 1019) P * IgG acl Level, GPL Q 4, 12.5 GPL 41 (31) 245 (24) 0.07 Positive, 23 GPL 14 (11) 64 (6) 0.06 IgM acl Level, MPL Q 4, 4.1 MPL 23 (18) 258 (25) 0.05 Positive, 11 MPL 4 (3) 40 (4) 0.6 IgG a 2 GPI Level, SGU NS Detectable, any 7 (5) 40 (4) NS Positive, 20 SGU 2 (2) 7 (1) NS IgM a 2 GPI Level, SMU NS Q 4, 2.0 SMU 25 (19) 263 (26) NS Positive, 20 SMU 5 (4) 41 (4) NS Values are numbers of patients (percentage); plus-minus values are mean SD. Q 4 indicates highest quartile; Q 1 3, lower 3 quartiles. * 2 test. Only 47 patients had any detectable IgG a 2 GPI (95th percentile). P the index MI, diabetes mellitus, smoking, pulmonary congestion, and ejection fraction 30%. In this model, IgG acl antibodies in the highest quartile of the distribution contributed an independent hazard ratio (HR) of 1.63 (95% CI 1.11 to 2.38; P 0.01) for recurrent coronary events. In contrast, IgM acl antibodies in the lower 3 quartiles of the distribution contributed an independent HR of 1.76 (95% CI 1.10 to 2.82; P 0.02) for recurrent coronary events. Because the IgG and IgM acl antibodies contributed comparable opposite effects, we explored the joint risk for patients in the high- and low-risk partitions of both acl antibody isotypes. The group of patients with IgM acl antibodies in the highest quartile and IgG acl antibodies in the lower 3 quartiles had the lowest risk and was chosen as the reference group. Patients with IgG acl antibodies in the highest quartile and IgM acl antibodies in the lower 3 quartiles had higher risks than any other acl antibody group and 3-fold higher risk than the reference group (P 0.001) (Table 4). The cutoff values for the upper quartiles of the IgG ( 12.5 GPL) and IgM ( 4.1 MPL) acl antibodies are lower than the values that are considered positive in the acl antibody assay that was used in our study ( 23 GPL for IgG and 11 MPL for IgM acl antibodies). When the data were analyzed according to the positive values, positive IgG and IgM acl antibodies were associated with hazard ratios of 2.0 (P 0.01) and 0.8 (P 0.6), respectively. The low number of positive IgG and IgM acl antibodies in the group of patients with events (Table 2) was the main obstacle to the interpretation of these results.
4 Bili et al Anticardiolipin Antibodies and Coronary Events 1261 Figure 1. Kaplan-Meier cumulative cardiac event rates for highest quartile (Q 4 ) vs lower 3 quartiles (Q 1 3 ) for IgG (A) and IgM (B) acl antibodies. The correlation coefficients for acl and a 2 GPI antibodies by isotype are shown in Table 5. A moderately strong correlation (r 0.50) was present only between IgM acl and a 2 GPI IgM antibodies. Discussion This report represents the largest study to date evaluating the association between acl and a 2 GPI antibodies and recurrent cardiac events in patients after MI. The data presented herein show that IgG acl antibodies in the highest quartile represent an independent risk factor for recurrent MI and cardiac death, with an HR of 1.63 after adjusting for other relevant clinical variables. This risk is comparable to other known risk factors for recurrent coronary events in our study: prior MI (HR 1.77), non insulin-dependent diabetes (HR 1.87), ejection fraction 30% (HR 1.69), and smoking (HR 1.81). Our data also revealed an inverse association of IgM acl antibody levels with recurrent cardiac events. Thus, patients with elevated IgG acl and low IgM acl antibodies had the highest risk compared with all other acl antibody groups. The association between myocardial infarction and IgG acl antibodies has been suggested in several smaller studies With regard to noncardiac events, IgG acl antibod-
5 1262 Circulation September 12, 2000 TABLE 3. Hazard Ratios of acl Antibodies in Multivariate Cox Model acl Antibodies HR* 95% CI P IgG (Q 4 :Q 1 3 ) IgM (Q 1 3 :Q 4 ) Q 1 3 indicates lower 3 quartiles; Q 4 : highest quartile. Cutoff values for Q 4 : IgG acl 12.5 GPL; IgM acl 4.1 MPL. Cox model includes adjustment for 6 clinical variables (P 0.1 to enter): age 60 y, diabetes mellitus, smoking, prior MI, pulmonary congestion, and ejection fraction *Ratio of the risk of having a cardiac event per unit time for patients in the top-risk partition vs patients in the lower-risk partition. ies at levels above the 95th percentile have been implicated as a significant risk factor for venous thrombosis or pulmonary embolus in a case-control study from the Physicians Health Study 2 and for first stroke in a large case-control study. 3 In other studies that found a positive association of the IgG acl antibodies with arterial thrombosis, information about the IgM acl antibodies was not reported 19 or the association was not conclusive. 8 Our study, because of its large size, had the power to detect such an association. Before our study, minimal information was available regarding the association between a 2 GPI antibodies and coronary events. We found no association between these antibodies (either IgG or IgM) with recurrent cardiac events despite a meaningful correlation (r 0.50) between acl IgM and a 2 GPI IgM antibodies. Our findings confirm and extend the only relevant study available in which only the IgG isotype was measured. 20 This result is consistent with Vaarala s 21 observation that a 2 GPI antibodies are infrequently detected in nonautoimmune patients with MI. The question of whether acl antibodies can be induced in response to tissue necrosis that occurs in MI is still unresolved. 22 However, there is clinical evidence that acl antibodies precede the development of first MI 12 and that acl antibody titers are stable for up to 3 months after MI. 11 These studies indicate that acl antibodies are not generated by tissue necrosis but rather they participate in the pathogenesis of MI. This hypothesis is biologically plausible because of the proinflammatory and procoagulant properties of these antibodies. The acl auto- TABLE 4. Joint Risks for Patients in High- and Low-Risk Partitions of IgG and IgM acl Antibodies IgG acl Antibodies IgM acl Antibodies Events/Patients, % HR P Q 1 3 Q 4 12/ * (6.8) Q 1 3 Q / (11) Q 4 Q 4 11/ (14) Q 4 Q / (14) Q 1 3 indicates lower 3 quartiles; Q 4, highest quartile. Cutoff values for Q 4 : IgG acl 12.5 GPL; IgM acl 4.1 MPL. *Group with the lowest risk (reference group). TABLE 5. Correlation Between acl and a 2 GPI Antibodies by Genotype Antibodies IgM acl IgG a 2 GPI IgM a 2 GPI IgG acl r 0.16 r 0.14 r 0.13 Igm acl r 0.08 r 0.50 IgG a 2 GPI r 0.12 P for all r correlation values. antibodies detected in SLE are primarily directed against the so-called cofactor proteins, including 2 GPI (the predominant cofactor), prothrombin, annexin V, thrombomodulin, and proteins C and S, among others. 26,30 Such cofactors share the property of being phospholipid-binding proteins with intrinsic anticoagulant activity. Hence, binding of acl antibodies may diminish the function of these anticoagulant systems. In addition, IgG acl antibodies enhance platelet activation and thromboxane production 27 and activate endothelial cells in the presence of 2 GPI. 28,29 The interplay among acl antibodies, the anticoagulant system, and the endothelial cells could contribute to the prothrombotic state that is central to the pathogenesis of recurrent MI. 16,31 A unique finding of our study is the reverse association of the IgM acl antibodies with recurrent cardiac events, even in the presence of IgG acl antibodies. Several non mutually exclusive mechanisms could account for this observation. IgM acl antibodies might represent protective natural autoantibodies 32 or they could have rheumatoid factor activity and thus play a beneficial role in immune homeostasis. 33 Alternatively, it could be postulated that the acl antibody response in our patients starts with a primary IgM antibody response against nonpathogenic epitopes that subsequently, through epitope spreading, results in the recognition of previously ignored pathogenic epitopes by antigen-selected IgG antibodies. 34 A hypothetical example of a protective initial IgM antibody response might be the binding and inhibition of the colonization of the vascular endothelium by infectious agents such as Chlamydia pneumoniae that may play a role in the development of atherosclerosis. 35,36 The ability of acl antibodies to recognize chlamydial antigens, or conversely, the ability of chlamydial infection to elicit acl antibodies, remains to be tested. This model is appealing because it is also consistent with the lack of association of recurrent coronary events with a 2 GPI antibodies that was observed in our study. Indeed, acl antibodies induced by infections do not recognize 2 GPI, 37 and these antibodies may be prevalent in our cohort of nonautoimmune patients. It should be noted that acl antibodies cross-react with oxidized LDL 25 and that antibodies against oxidized LDL have been implicated in the development of atherosclerosis. 22 When considered that both C pneumoniae and chlamydial hsp60, an inflammatory antigen that was recently localized in atheromas, can induce cellular oxidation of LDL, 38 a reasonable link between chlamydial infection, acl antibodies, and atherosclerosis emerges. In summary, IgG acl antibodies are an independent risk factor for recurrent cardiac events in this large population of nonautoimmune patients. Our findings contribute new data in the ongoing research for identification of additional coronary risk factors. 39 At present, the use of IgG acl antibodies to
6 Bili et al Anticardiolipin Antibodies and Coronary Events 1263 stratify patients for coronary risk is limited by the heterogeneity of these antibodies, 40 the available commercial kits, 41 and the lack of standardization of the acl antibody assays between the different laboratories. 42 As we learn more about the different specificities of the acl antibodies and more standardized assays develop, acl antibodies may become useful for identifying patients at risk for coronary events. Although high levels IgG and low levels of IgM acl antibodies convey independent risk, the predictive value of these antibodies is too low for use in risk-stratification application at this time. Acknowledgments This study was supported by National Institutes of Health grants HL and HL and by the University of Rochester School of Medicine and Dentistry. We thank Elsa Welch for technical support and Dr Elena Rey for advice with the ELISA tests. We thank Dr John Condemi for reviewing the manuscript. References 1. Wilson WA, Gharavi AE, Koike T, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome. Arthritis Rheum. 1999;42: Ginsburg KS, Liang MH, Newcomer L, et al. Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Ann Intern Med. 1992;117: Antiphospholipid Antibodies in Stroke Study (APASS) Group. Anticardiolipin antibodies are an independent risk factor for first ischemic stroke. Neurology. 1993;43: Sheng Y, Kandiah DA, Krilis SA. 2 -Glycoprotein I: target antigen for antiphospholipid antibodies : immunological and molecular aspects. Lupus. 1998;2:S5 S9. 5. Tsutsumi A, Matsuura E, Ichikawa K, et al. Antibodies to 2 -glycoprotein I and clinical manifestations in patients with systemic lupus erythematosus. Arthritis Rheum. 1996;39: Roubey RAS, Maldonado MA, Byrd SN. Comparison of an enzymelinked immunosorbent assay for antibodies to 2 -glycoprotein I and a conventional anticardiolipin immunoassay. Arthritis Rheum. 1996;39: Cabiedes J, Cabral AR, Alarcon-Segovia D. Clinical manifestations of the antiphospholipid syndrome in patients with systemic lupus erythematosus associate more strongly with anti- 2 -glycoprotein I than with antiphospholipid antibodies. J Rheumatol. 1995;22: Morton KE, Krilis SA, Baron DW, et al. Coronary artery bypass graft failure: an autoimmune phenomenon? Lancet. 1986;2: Hamsten A, Bjorkholm M, Norberg R, et al. Antibodies to cardiolipin in young survivors of myocardial infarction: an association with recurrent cardiovascular events. Lancet. 1986;1: Klemp P, Cooper RC, Strauss FJ, et al. Anticardiolipin antibodies and ischaemic heart disease. Clin Exp Immunol. 1988;74: Zuckerman E, Toubi E, Shiran A, et al. Anticardiolipin antibodies and acute myocardial infarction in non-systemic lupus erythematosus patients: a controlled prospective study. Am J Med. 1996;171: Vaarala O, Manttari M, Manninen V, et al. Anticardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men. Circulation. 1995;91: Wu R, Nityanand S, Berglund L, et al. Antibodies against cardiolipin and oxidatively modified LDL in 50-year-old men predict myocardial infarction. Arterioscler Thromb Vasc Biol. 1997;17: Sletnes KE, Smith P, Abdelnoor M, et al. Antiphospholipid antibodies after myocardial infarction and their relation to mortality, reinfarction, and non-haemorrhagic stroke. Lancet. 1992;339: Phadke KV, Phillips RA, Clarke DTR, et al. Anticardiolipin antibodies in ischaemic heart disease: marker or myth? Br Heart J. 1993;69: Moss AJ, Goldstein RE, Marder VJ, et al. Thrombogenic factors and recurrent coronary events. Circulation. 1999;99: Harris EN, Gharavi AE, Patel SP, et al. Evaluation of the anti-cardiolipin antibody test: report of an international workshop held 4 April Clin Exp Immunol. 1987;68: Erickson EN, Najmey SS, Keil LB, et al. Reference calibrators for IgG antibodies to 2 -glycoprotein I: preparation, properties and availability to investigators. Clin Chem. 1996;42: Levine SR, Salowich-Palm L, Sawaya KL, et al. IgG anticardiolipin antibody titer 40 GPL and the risk of subsequent thrombo-occlusive events and death. Stroke. 1997;28: Vaarala O, Puurunen M, Manttari M, et al. Antibodies to prothrombin imply a risk of myocardial infarction in middle-aged men. Thromb Haemost. 1996;75: Vaarala O. Antiphospholipid antibodies and myocardial infarction. Lupus. 1998;7(suppl 2):S132 S Vaarala O. Antiphospholipid antibodies and atherosclerosis. Lupus. 1996; 5: Shoenfeld Y, Harats D, George J. Atherosclerosis and the antiphospholipid syndrome: a link unraveled? Lupus. 1998;7(suppl 2):S140 S Hasunuma Y, Matsuura E, Katahira MT, et al. Involvement of 2 -glycoprotein I and anticardiolipin antibodies in oxidatively modified lowdensity lipoprotein uptake by macrophages. Clin Exp Immunol. 1997;107: Vaarala O, Alftan G, Jauhiainen M, et al. Crossreaction between antibodies to oxidised low-density lipoprotein and to cardiolipin in systemic lupus erythematosus. Lancet. 1993;341: Roubey RAS. Mechanisms of autoantibody-mediated thrombosis. Lupus. 1998;7(suppl 2):S114 S Martinuzzo ME, Maclouf J, Carreras LO, et al. Antiphospholipid antibodies enhance thrombin-induced platelet activation and thromboxane formation. Thromb Haemost. 1993;70: Cuadrado MJ. Thrombosis in primary antiphospholipid syndrome: a pivotal role for monocyte tissue factor expression. Arthritis Rheum. 1997; 40: Simantov R, LaSala JM, Lo SK, et al. Activation of cultured vascular endothelial cells by antiphospholipid antibodies. J Clin Invest. 1995;96: Sheng Y, Kandiah DA, Krilis SA. 2 -glycoprotein I: target antigen for antiphospholipid antibodies: immunological and molecular aspects. Lupus. 1998;7(suppl 2):S5 S DeWood MA, Spores J, Notske R, et al. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med. 1980;303: Coutinho A, Kazatchkine MD, Avrameas S. Natural autoantibodies. Curr Opin Immunol. 1995;7: Carson DA, Chen PP, Kipps TJ. New roles for rheumatoid factor. J Clin Invest. 1991;87: Vanderlugt CL, Begolka WS, Neville KL, et al. The functional significance of epitope spreading and its regulation by costimulatory molecules. Immunol Rev. 1998;164: Melnick SL, Shahar E, Folsom AR, et al. Past infection by Chlamydia pneumoniae strain TWAR and asymptomatic carotid atherosclerosis: Atherosclerosis Risk in Communities (ARIC) Study Investigators. Am J Med. 1993;95: Laurila A, Bloigu A, Nayha S, et al. Chronic Chlamydia pneumoniae infection is associated with a serum lipid profile known to be a risk factor for atherosclerosis. Arterioscler Thromb Vasc Biol. 1997;17: Hunt JE, McNeil HP, Morgan GJ, et al. A phospholipid- 2 -glycoprotein I complex is an antigen for anticardiolipin antibodies occurring in autoimmune disease but not in infection. Lupus. 1992;1: Kalayoglu MV, Hoerneman B, LaVerda D, et al. Cellular oxidation of low-density lipoprotein by Chlamydia pneumoniae. J Infect Dis. 1999; 180: Ridker PM. Evaluating novel cardiovascular risk factors: can we better predict heart attacks? Ann Intern Med. 1999;130: Roubey RA. Autoantibodies to phospholipid-binding plasma proteins: a new view of lupus anticoagulant and other antiphospholipid autoantibodies. Blood. 1994;84: Fevaloro EJ, Silvestrini R, Mohammed A. Clinical utility of anticardiolipin antibody assays: high inter-laboratory variation and limited consensus by participants of external quality assurance programs signals a cautious approach. Pathology. 1999;31: Reber G, Arvieux J, Comby E, et al. Multicenter evaluation of nine commercial kits for the quantitation of anticardiolipin antibodies. Thromb Haemost. 1995;73:
Anti β 2. -Glycoprotein I and Antiphosphatidylserine Antibodies Are Predictors of Arterial Thrombosis in Patients With Antiphospholipid Syndrome
Coagulation and Transfusion Medicine / PREDICTIVE VALUE OF ANTIPHOSPHOLIPID ANTIBODIES Anti β -Glycoprotein I and Antiphosphatidylserine Antibodies Are Predictors of Arterial Thrombosis in Patients With
More informationAnticardiolipin Antibodies in Patients With Type 2 Diabetes Mellitus
CM&R Rapid Release. Published online ahead of print February 26, 2009 as doi:10.3121/cmr.2008.828 Original Research Anticardiolipin Antibodies in Patients With Type 2 Diabetes Mellitus José María Calvo-Romero,
More informationT he antiphospholipid syndrome (APS) is a thrombophilic
1639 EXTENDED REPORT ntiphospholipid antibody tests: spreading the net M L ertolaccini, S Gomez, J F P Pareja, Theodoridou, G Sanna, G R V Hughes, M Khamashta... See end of article for authors affiliations...
More informationAntiphospholipid antibodies are a heterogeneous family
Seasonal Distribution of Antiphospholipid Antibodies Thanh-Ha Luong, MD; Jacob H. Rand, MD; Xiao-Xuan Wu, MD; James H. Godbold, PhD; Mayra Gascon-Lema, MS; Stanley Tuhrim, MD Background and Purpose The
More informationThrombophilia. Dr. A Sarrafnejad PhD Dep. Immunology School of public health TUMS
Autoimmune Thrombophilia Dr. A Sarrafnejad PhD Dep. Immunology School of public health TUMS Saraf@sina.tums.ac.ir Acquired Thrombophilia HIT PNH Cyckle cell Anemia Myeloproliferative lf Diseases Thrombocytosis
More informationManifestation of Antiphospholipid Syndrome among Saudi patients :examining the applicability of sapporo Criteria
Manifestation of Antiphospholipid Syndrome among Saudi patients :examining the applicability of sapporo Criteria Farjah H AlGahtani Associate professor,md,mph Leukemia,Lymphoma in adolescent,thromboembolic
More informationAntiphospholipid Syndrome
Antiphospholipid Syndrome EliA Cardiolipin and EliA β2-glycoprotein I Fully Automated Testing for Antiphospholipid Syndrome (APS) Testing for APS according to classification criteria determination of anti-β2-glycoprotein
More informationThe Comparison of Acute Myocardial Infarction Serum Anticardiolipin Antibody with Healthy Subjects, in Gorgan (Northern Iran)
Pakistan Journal of Biological Sciences 16 (2): 92-96, 2013 ISSN 1028-8880 I DOI: 10.3923/pjbs.2013.92.96 2013 Asian Network for Scientific Information The Comparison of Acute Myocardial Infarction Serum
More informationLupus as a risk factor for cardiovascular disease
Lupus as a risk factor for cardiovascular disease SØREN JACOBSEN Department Rheumatology, Rigshospitalet Søren Jacobsen Main sponsors: Gigtforeningen Novo Nordisk Fonden Rigshospitalet Disclaimer: Novo
More informationKey words: antiphospholipid syndrome, trombosis, pathogenesis
26. XI,. 4/2011,.,..,..,., -..,,. 2GPI. -,.,,., -,, -, -,,,,, IL-1, IL-2, IL-6, IL-8, IL-12, IL-10, TNF, INF-. :,, N. Stoilov, R. Rashkov and R. Stoilov. ANTIPHOSPHOLIPID SYNDROME HISTORICAL DATA, ETI-
More informationAre there still any valid indications for thrombophilia screening in DVT?
Carotid artery stenosis and risk of stroke Are there still any valid indications for thrombophilia screening in DVT? Armando Mansilha MD, PhD, FEBVS Faculty of Medicine of University of Porto Munich, 2016
More informationSupplementary Online Content
1 Supplementary Online Content Friedman DJ, Piccini JP, Wang T, et al. Association between left atrial appendage occlusion and readmission for thromboembolism among patients with atrial fibrillation undergoing
More informationCurrent View of the Treatment of Antiphospholipid Syndrome
GROUPE HOSPITALIER PITIE SALPETRIERE Current View of the Treatment of Antiphospholipid Syndrome Pr Zahir AMOURA Department of Internal Medicine French National Reference center for SLE and APS Hôpital
More informationANTI-PHOSPHATIDYLSERINE ANTIBODIES IN ACUTE MYOCARDIAL INFARCTION
American Journal of Immunology 9 (4): 96-100, 2013 ISSN: 1553-619X 2013 Science Publication doi:10.3844/ajisp.2013.96.100 Published Online 9 (4) 2013 (http://www.thescipub.com/aji.toc) ANTI-PHOSPHATIDYLSERINE
More informationTHE PRESENCE OF ANTI-PHOSPHATIDYLETHANOLAMINE ANTIBODIES IN ACUTE MYOCARDIAL INFARCTION
OnLine Journal of Biological Sciences 13 (4): 126-130, 2013 ISSN: 1608-4217 2013 A.S. Jahromi et al., This open access article is distributed under a Creative Commons Attribution (CC-BY) 3.0 license doi:10.3844/ojbssp.2013.126.130
More informationThrombophilia. Diagnosis and Management. Kevin P. Hubbard, DO, FACOI
Thrombophilia Diagnosis and Management Kevin P. Hubbard, DO, FACOI Clinical Professor of Medicine Kansas City University of Medicine and Biosciences-College of Osteopathic Medicine Kansas City, Missouri
More informationPatient characteristics Intervention Comparison Length of followup
ISCHAEMIA TESTING CHAPTER TESTING FOR MYCOCARDIAL ISCHAEMIA VERSUS NOT TESTING FOR MYOCARDIAL ISCHAEMIA Ref ID: 4154 Reference Wienbergen H, Kai GA, Schiele R et al. Actual clinical practice exercise ing
More informationMandana Nikpour 1,2, Murray B Urowitz 1*, Dominique Ibanez 1, Paula J Harvey 3 and Dafna D Gladman 1. Abstract
RESEARCH ARTICLE Open Access Importance of cumulative exposure to elevated cholesterol and blood pressure in development of atherosclerotic coronary artery disease in systemic lupus erythematosus: a prospective
More informationAntiphospholipid Syndrome ( APS)
Antiphospholipid Syndrome ( APS) Edward John Walter Bowie, MD Mayo Medical School the first to identify APS as an acquired thrombophilia Graham Robert Vivian Hughes MD FRCP Unit Rayne Institute St Thomas
More informationA ntiphospholipid antibodies (apl) are a group of
1106 EXTENDED REPORT Anticardiolipin, anti-b 2 -glycoprotein I and antiprothrombin antibodies in black South African patients with infectious disease S Loizou, S Singh, E Wypkema, R A Asherson... See end
More informationAntiphospholipid Antibody Testing: Which Are Most Useful for Diagnosis?
Rheum Dis Clin N Am 32 (2006) 455 463 Antiphospholipid Antibody Testing: Which Are Most Useful for Diagnosis? Maria Laura Bertolaccini, MD, PhD*, Graham R.V. Hughes, MD, FRCP Lupus Research Unit, The Rayne
More informationAntiplatelet agents treatment
Session III Comprehensive management of diabetic patients Antiplatelet agents treatment Chonnam National University Hospital Department of Internal Medicine Dong-Hyeok Cho CONTENTS Introduction Prothrombotic
More informationACLA. i- Islet Cell Antibodies. -
( ) : ACLA. ( ACLA) IgM IgG ACLA. :. (IgM IgG) ACLA. /± :. ( ANA) ( RF) (% ) ( IgM IgG) ACLA ACLA IgM ACLA IgG.(% ) ACLA.(/±/ GPLU/ml /±/) [ACLA(+)] ). HbA1C ( ) ( ACLA(-) ACLA (+). ACLA (+) :.(% ) ACLA..
More informationMohammadreza Tabatabaei IBTO COAG LAB
Tests for the Evaluation of Lupus Anticoagulants t Mohammadreza Tabatabaei MSc Hematology blood bank MSc Hematology blood bank IBTO COAG LAB Lupus Anticoagulants General Background Lupus anticoagulants
More informationImpaired Chronotropic Response to Exercise Stress Testing in Patients with Diabetes Predicts Future Cardiovascular Events
Diabetes Care Publish Ahead of Print, published online May 28, 2008 Chronotropic response in patients with diabetes Impaired Chronotropic Response to Exercise Stress Testing in Patients with Diabetes Predicts
More informationThe Impact of Smoking on Acute Ischemic Stroke
Smoking The Impact of Smoking on Acute Ischemic Stroke Wei-Chieh Weng, M.D. Department of Neurology, Chang-Gung Memorial Hospital, Kee-Lung, Taiwan Smoking related mortality Atherosclerotic vascular disease
More informationDRG Anti-Phospholipid Screen IgG/IgM ELISA (EIA-3591) USA: RUO Revised 1 Aug rm (Vers. 5.1)
This kit is intended for Research Use Only. Not for use in diagnostic procedures. Please use only the valid version of the package insert provided with the kit. 1. NAME AND INTENDED USE The Anti-Phospholipid
More informationORIGINAL PAPERS. Marek Cieśla 1, B D, Ewa Wypasek 1, 2, B D 1, 2, A, E, F. Abstract
ORIGINAL PAPERS Adv Clin Exp Med 2014, 23, 5, 729 733 ISSN 1899 5276 Copyright by Wroclaw Medical University Marek Cieśla 1, B D, Ewa Wypasek 1, 2, B D 1, 2, A, E, F, Anetta Undas IgA Antiphospholipid
More informationIgG and IgM Anticardiolipin Antibodies Following Treatment With Infliximab Plus Methotrexate in Patients With Early Rheumatoid Arthritis
ARTHRITIS & RHEUMATISM Vol. 54, No. 9, September 2006, pp 2840 2844 DOI 10.1002/art.22054 2006, American College of Rheumatology IgG and IgM Anticardiolipin Antibodies Following Treatment With Infliximab
More informationThromboembolic risk in patients with high titre anticardiolipin and multiple antiphospholipid antibodies
TH0209_0116 2003 Schattauer GmbH, Stuttgart 1 Blood Coagulation, Fibrinolysis and Cellular Haemostasis Thromboembolic risk in patients with high titre anticardiolipin and multiple antiphospholipid antibodies
More informationTHROMBOSIS PRODUCT HIGHLIGHTS
PRODUCT HIGHLIGHTS AESKU.DIAGNOSTICS has extensive experience and know-how in the Anti-Phospholipid Syndrome (APS) field and offers the most comprehensive panel of anti-phospholipid tests, employing highly
More informationTroponin I elevation increases the risk of death and stroke in patients with atrial fibrillation a RE-LY substudy. Ziad Hijazi, MD
Troponin I elevation increases the risk of death and stroke in patients with atrial fibrillation a RE-LY substudy Ziad Hijazi, MD Uppsala Clinical Research Center (UCR) Uppsala University, Sweden Co-authors:
More informationIntroduction. Keywords: Infrainguinal bypass; Prognosis; Haemorrhage; Anticoagulants; Antiplatelets.
Eur J Vasc Endovasc Surg 30, 154 159 (2005) doi:10.1016/j.ejvs.2005.03.005, available online at http://www.sciencedirect.com on Risk of Major Haemorrhage in Patients after Infrainguinal Venous Bypass Surgery:
More information9/29/2015. Primary Prevention of Heart Disease: Objectives. Objectives. What works? What doesn t?
Primary Prevention of Heart Disease: What works? What doesn t? Samia Mora, MD, MHS Associate Professor, Harvard Medical School Associate Physician, Brigham and Women s Hospital October 2, 2015 Financial
More informationTHE CARDIOVASCULAR INFLAMMATORY CONTINUUM DR AB MAHARAJ
THE CARDIOVASCULAR INFLAMMATORY CONTINUUM DR AB MAHARAJ Disclosures: On National Advisory Boards of: (1) Pfizer Pharmaceuticals (2) MSD (3) Roche Pharmaceuticals (4) Abbott International: AfME Rheumatology
More informationInter-regional differences and outcome in unstable angina
European Heart Journal (2000) 21, 1433 1439 doi:10.1053/euhj.1999.1983, available online at http://www.idealibrary.com on Inter-regional differences and outcome in unstable angina Analysis of the International
More informationLong-term prognostic value of N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP) changes within one year in patients with coronary heart disease
Long-term prognostic value of N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP) changes within one year in patients with coronary heart disease D. Dallmeier 1, D. Rothenbacher 2, W. Koenig 1, H. Brenner
More informationEvaluation of antiphospholipid antibodies testing for the diagnosis of antiphospholipid syndrome
Original Article Evaluation of antiphospholipid antibodies testing for the diagnosis of antiphospholipid syndrome Paula Gonçalves Perches¹, Daniela Pezzutti Domingues¹, Andréia Latanza Gomes², Augusta
More informationPrimary Prevention of Stroke
Primary Prevention of Stroke Dr Chris Ellis Cardiologist Green Lane CVS Service, Auckland City Hospital & Auckland Heart Group, Mercy Hospital, Auckland 67 Pages Long, 735 References 29 Sub-Headings for
More informationCIC Edizioni Internazionali. Cardio-metabolic comorbidities in rheumatoid arthritis and SLE. Review. 120 Clinical Dermatology 2013; 1 (2):
Review Cardio-metabolic comorbidities in rheumatoid arthritis and SLE Andrea Doria Division of Rheumatology University of Padua, Italy Address for correspondence: Division of Rheumatology University of
More informationIMMUNOWELL CARDIOLIPIN ANTIBODY (IGM) TEST
IMMUNOWELL CARDIOLIPIN ANTIBODY (IGM) TEST Product No. 3100 For In Vitro Diagnostic Use SEE CALIBRATION VALUES, TABLE 2, PAGE 3 INTENDED USE The ImmunoWELL Cardiolipin Antibody (IgM) Test is an enzyme
More informationAnti-Cardiolipin Antibodies and Overall Survival in a Large Cohort: Preliminary Report
Clinical Chemistry 52:6 1040 1044 (2006) Hemostasis and Thrombosis Anti-Cardiolipin Antibodies and Overall Survival in a Large Cohort: Preliminary Report Georg Endler, 1 Claudia Marsik, 1,2 Bernd Jilma,
More informationPrevalence of antiphospholipid auto antibodies in patients with thrombosis
EUROPEAN ACADEMIC RESEARCH Vol. IV, Issue 6/ September 2016 ISSN 2286-4822 www.euacademic.org Impact Factor: 3.4546 (UIF) DRJI Value: 5.9 (B+) Prevalence of antiphospholipid auto antibodies in patients
More informationV. Roldán, F. Marín, B. Muiña, E. Jover, C. Muñoz-Esparza, M. Valdés, V. Vicente, GYH. Lip
PLASMA VON WILLEBRAND FACTOR LEVELS ARE AN INDEPENDENT RISK FACTOR ADVERSE EVENTS IN HIGH RISK ATRIAL FIBRILLATION PATIENTS TAKING ORAL ANTICOAGULATION THERAPY V. Roldán, F. Marín, B. Muiña, E. Jover,
More informationHEPARIN-INDUCED THROMBOCYTOPENIA (HIT)
HEPARIN-INDUCED THROMBOCYTOPENIA (HIT) OBJECTIVE: To assist clinicians with the investigation and management of suspected and documented heparin-induced thrombocytopenia (HIT). BACKGROUND: HIT is a transient,
More informationClinical Investigation and Reports. Risk Factors for Cardiovascular Disease in Systemic Lupus Erythematosus
Clinical Investigation and Reports Risk Factors for Cardiovascular Disease in Systemic Lupus Erythematosus Elisabet Svenungsson, MD; Kerstin Jensen-Urstad, MD, PhD; Mikael Heimbürger, MD, PhD; Angela Silveira,
More informationName and Intended Use
Name and Intended Use Anti-Prothrombin IgG/IgM is an indirect solid phase enzyme immunoassay (ELISA) for the quantitative measurement of IgG and IgM class autoantibodies against Prothrombin in human serum
More informationRole of Clopidogrel in Acute Coronary Syndromes. Hossam Kandil,, MD. Professor of Cardiology Cairo University
Role of Clopidogrel in Acute Coronary Syndromes Hossam Kandil,, MD Professor of Cardiology Cairo University ACS Treatment Strategies Reperfusion/Revascularization Therapy Thrombolysis PCI (with/ without
More informationJournal of the American College of Cardiology Vol. 35, No. 5, by the American College of Cardiology ISSN /00/$20.
Journal of the American College of Cardiology Vol. 35, No. 5, 2000 2000 by the American College of Cardiology ISSN 0735-1097/00/$20.00 Published by Elsevier Science Inc. PII S0735-1097(00)00546-5 CLINICAL
More informationORIGINAL INVESTIGATION
ORIGINAL INVESTIGATION High Impact of Antiphospholipid Syndrome on Irreversible Organ Damage and Survival of Patients With Systemic Lupus Erythematosus Guillermo Ruiz-Irastorza, MD, PhD; Maria-Victoria
More informationSupplementary Table S1: Proportion of missing values presents in the original dataset
Supplementary Table S1: Proportion of missing values presents in the original dataset Variable Included (%) Missing (%) Age 89067 (100.0) 0 (0.0) Gender 89067 (100.0) 0 (0.0) Smoking status 80706 (90.6)
More informationRheumatoid Arthritis: An update for non rheumatologists
Rheumatoid Arthritis: An update for non rheumatologists Dimitrios Pappas, M.D., M.P.H. Assistant Professor of Medicine Columbia University, College of Physicians & Surgeons Director of Rheumatology Athens
More informationLack of Effect of Beta-blocker Therapy in Patients with ST-elevation Acute Myocardial Infarction in PCI Era
Lack of Effect of Beta-blocker Therapy in Patients with ST-elevation Acute Myocardial Infarction in PCI Era B. Bao 1, N. Ozasa 1, T. Morimoto 2, Y. Furukawa 3, M. Shirotani 4, H. Ogawa 5, C. Tei 6, H.
More informationAntiphospholipid Antibody Syndrome: Management Issues for the Hematologist
Antiphospholipid Antibody Syndrome: Management Issues for the Hematologist Wisconsin Institute of Discovery Karen Rossi/Bristol-Myers Squibb Morey A. Blinder, MD Washington University, St. Louis, MO March
More informationClassification of Endothelial Dysfunction. Stefano Taddei Department of Internal Medicine University of Pisa, Italy
Classification of Endothelial Dysfunction Stefano Taddei Department of Internal Medicine University of Pisa, Italy Pathogenesis of atherosclerosis from endothelial dysfunction to clinical disease endothelial
More informationAntihypertensive Trial Design ALLHAT
1 U.S. Department of Health and Human Services Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic National Institutes
More informationImplantable Cardioverter Defibrillator Therapy in MADIT II Patients with Signs and Symptoms of Heart Failure
Implantable Cardioverter Defibrillator Therapy in MADIT II Patients with Signs and Symptoms of Heart Failure Wojciech Zareba Postinfarction patients with left ventricular dysfunction are at increased risk
More informationBy Graham C. Wong, MD; and Christian Constance, MD. therapy in reducing long-term cardiovascular
Lipid-Lowering Therapy For Acute Coronary Syndromes There is a large amount of evidence that supports the early use of statins in the treatment of acute coronary syndromes. The anti-inflammatory, anti-thrombotic
More informationDISCLOSURE. Presented by: Merav Sendowski, MD Oregon Health and Science University
Thrombophilia! DISCLOSURE Presented by: Merav Sendowski, MD Oregon Health and Science University Created by: Thomas Deloughery, MD Oregon Health and Science University Current Relevant Financial Relationship(s)
More informationLOUISVILLE APL DIAGNOSTICS, INC. APL ELISA IgM Kit
LOUISVILLE APL DIAGNOSTICS, INC. APL ELISA IgM Kit REF LAPL-K-AP-M-0 For the Measurement of IgM Anticardiolipin Antibodies IVD For In Vitro Diagnostic Use Manufactured by: Louisville APL Diagnostics, Inc.
More informationDECLARATION OF CONFLICT OF INTEREST
DECLARATION OF CONFLICT OF INTEREST Is there a mortality risk associated with aspirin use in heart failure? Results from a large community based cohort Margaret Bermingham, Mary-Kate Shanahan, Saki Miwa,
More informationC-Reactive Protein and Your Heart
C-Reactive Protein and Your Heart By: James L. Holly, MD Inflammation is the process by which the body responds to injury. Laboratory evidence and findings at autopsy studies suggest that the inflammatory
More informationThe Antiphospholipid Syndrome
The Antiphospholipid Syndrome 1 / 6 2 / 6 3 / 6 The Antiphospholipid Syndrome Antiphospholipid antibody syndrome (commonly called antiphospholipid syndrome or APS) is an autoimmune disease present mostly
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the
More informationJ.DelgadoAlves,S.KumarandD.A.Isenberg
Rheumatology 2003;42:893 899 doi:10.1093/rheumatology/keg248, available online at www.rheumatology.oupjournals.org Advance Access publication 16 April 2003 Cross-reactivity between anti-cardiolipin, anti-high-density
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Bucholz EM, Butala NM, Ma S, Normand S-LT, Krumholz HM. Life
More informationThe JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009
The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009 Learning Objectives 1. Understand the role of statin therapy in the primary and secondary prevention of stroke 2. Explain
More informationIS PRE-CLINICAL AUTOIMMUNITY BENIGN?
IS PRE-CLINICAL AUTOIMMUNITY BENIGN? Darcy S. Majka MD, MS Disclosures I have no significant financial or other relationship with the manufacturers of any product or services. Dr. Teodorescu (coauthor)
More informationSupplement materials:
Supplement materials: Table S1: ICD-9 codes used to define prevalent comorbid conditions and incident conditions Comorbid condition ICD-9 code Hypertension 401-405 Diabetes mellitus 250.x Myocardial infarction
More informationBehind LDL: The Metabolism of ApoB, the Essential Apolipoprotein in LDL and VLDL
Behind LDL: The Metabolism of ApoB, the Essential Apolipoprotein in LDL and VLDL Sung-Joon Lee, PhD Division of Food Science Institute of Biomedical Science and Safety Korea University Composition of Lipoproteins:
More informationA Randomized Comparison of Clopidogrel and Aspirin Versus Ticlopidine and Aspirin After the Placement of Coronary Artery Stents
Journal of the American College of Cardiology Vol. 41, No. 6, 2003 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00 Published by Elsevier Science Inc. doi:10.1016/s0735-1097(02)02974-1
More informationExercise treadmill testing is frequently used in clinical practice to
Preventive Cardiology FEATURE Case Report 55 Commentary 59 Exercise capacity on treadmill predicts future cardiac events Pamela N. Peterson, MD, MSPH 1-3 David J. Magid, MD, MPH 3 P. Michael Ho, MD, PhD
More informationVENOUS THROMBOEMBOLISM AND CORONARY ARTERY DISEASE: IS THERE A LINK?
VENOUS THROMBOEMBOLISM AND CORONARY ARTERY DISEASE: IS THERE A LINK? Ayman El-Menyar (1), MD, Hassan Al-Thani (2),MD (1)Clinical Research Consultant, (2) Head of Vascular Surgery, Hamad General Hospital
More informationGALECTIN-3 PREDICTS LONG TERM CARDIOVASCULAR DEATH IN HIGH-RISK CORONARY ARTERY DISEASE PATIENTS
GALECTIN-3 PREDICTS LONG TERM CARDIOVASCULAR DEATH IN HIGH-RISK CORONARY ARTERY DISEASE PATIENTS Table of Contents List of authors pag 2 Supplemental figure I pag 3 Supplemental figure II pag 4 Supplemental
More informationAvailable Online at CODEN: IJRSFP (USA) Vol. 9, Issue, 3(L), pp , March, 2018.
ISSN: 0976-3031 Available Online at http://www.recentscientific.com CODEN: IJRSFP (USA) International Journal of Recent Scientific Research Vol. 9, Issue, 3(L), pp. 25504-25508, March, 2018 Research Article
More informationCVD risk assessment using risk scores in primary and secondary prevention
CVD risk assessment using risk scores in primary and secondary prevention Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Honoraria for consulting and speaker activities
More informationCase Report Lower Limb Ischemia: Aortoiliac Thrombosis Related to Antiphospholipid Syndrome (APS) Case Report and Review of the Literature
Case Reports in Surgery Volume 2013, Article ID 536971, 4 pages http://dx.doi.org/10.1155/2013/536971 Case Report Lower Limb Ischemia: Aortoiliac Thrombosis Related to Antiphospholipid Syndrome (APS) Case
More information2-Glycoprotein 1 as a marker of antiphospholipid syndrome in women with recurrent pregnancy loss
FERTILITY AND STERILITY VOL. 73, NO. 3, MARCH 2000 Copyright 2000 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. 2-Glycoprotein 1 as
More informationA: Epidemiology update. Evidence that LDL-C and CRP identify different high-risk groups
A: Epidemiology update Evidence that LDL-C and CRP identify different high-risk groups Women (n = 27,939; mean age 54.7 years) who were free of symptomatic cardiovascular (CV) disease at baseline were
More informationRedgrave JN, Coutts SB, Schulz UG et al. Systematic review of associations between the presence of acute ischemic lesions on
6. Imaging in TIA 6.1 What type of brain imaging should be used in suspected TIA? 6.2 Which patients with suspected TIA should be referred for urgent brain imaging? Evidence Tables IMAG1: After TIA/minor
More informationPart 1 Risk Factors and Atherosclerosis. LO1. Define the Different Forms of CVD
Week 3: Cardiovascular Disease Learning Outcomes: 1. Define the difference forms of CVD 2. Describe the various risk factors of CVD 3. Describe atherosclerosis and its stages 4. Describe the role of oxidation,
More informationSupplementary Online Content
Supplementary Online Content Leibowitz M, Karpati T, Cohen-Stavi CJ, et al. Association between achieved low-density lipoprotein levels and major adverse cardiac events in patients with stable ischemic
More informationFOCUS ON CARDIOVASCULAR DISEASE
The Consequences of Vitamin D Deficiency: FOCUS ON CARDIOVASCULAR DISEASE Vitamin D deficiency is a global health problem. With all the medical advances of the century, vitamin D deficiency is still epidemic.
More informationCardiovascular Disorders Lecture 3 Coronar Artery Diseases
Cardiovascular Disorders Lecture 3 Coronar Artery Diseases By Prof. El Sayed Abdel Fattah Eid Lecturer of Internal Medicine Delta University Coronary Heart Diseases It is the leading cause of death in
More informationSummary of the 11th International Congress on Antiphospholipid Antibodies, Sydney, Australia, November 2004
Journal of Reproductive Immunology 66 (2005) 85 90 Meeting report Summary of the 11th International Congress on Antiphospholipid Antibodies, Sydney, Australia, November 2004 The 11th International Congress
More informationUniversity of Pretoria
University of Pretoria Serodiagnostic Procedures Performed in the Department of Immunology Dr Pieter WA Meyer 1.Autoimmune Diseases Automated Anti-nuclear antibodies Anti-gliadin/ tissue transglutaminase
More informationThe inhibition of CETP: From simply raising HDL-c to promoting cholesterol efflux and lowering of atherogenic lipoproteins Prof Dr J Wouter Jukema
The inhibition of CETP: From simply raising HDL-c to promoting cholesterol efflux and lowering of atherogenic lipoproteins Prof Dr J Wouter Jukema Dept Cardiology, Leiden University Medical Center, Leiden,
More informationTicagrelor compared with clopidogrel in patients with acute coronary syndromes the PLATO trial
compared with clopidogrel in patients with acute coronary syndromes the PLATO trial August 30, 2009 at 08.00 CET PLATO background In NSTE-ACS and STEMI, current guidelines recommend 12 months aspirin and
More informationLupus anticoagulant and anticardiolipin antibodies in SLE with secondary Antiphospholipid Antibody Syndrome
Turk J Hematol 2007; 24:69-74 Turkish Society of Hematology RESEARCH ARTICLE Lupus anticoagulant and anticardiolipin antibodies in SLE with secondary Antiphospholipid Antibody Syndrome Shveta Garg, Annamma
More informationPredictors of cardiac allograft vasculopathy in pediatric heart transplant recipients
Pediatr Transplantation 2013: 17: 436 440 2013 John Wiley & Sons A/S. Pediatric Transplantation DOI: 10.1111/petr.12095 Predictors of cardiac allograft vasculopathy in pediatric heart transplant recipients
More informationAntibodies to anticardiolipin (acl) and 2 -glycoprotein 1
Original Contributions 2 -Glycoprotein 1 Dependent Anticardiolipin Antibodies and Risk of Ischemic Stroke and Myocardial Infarction The Honolulu Heart Program Robin L. Brey, MD; Robert D. Abbott, PhD;
More informationSupplemental Figures and Legends
Supplemental Figures and Legends Online Figure 1. 18 year old female with SLE and acute homonymous hemianopsia, confusional state, and cognitive dysfunction. A. This TEE four chamber view demonstrates
More informationWhich drug do you prefer for stable CAD? - P2Y12 inhibitor
Which drug do you prefer for stable CAD? - P2Y12 inhibitor Jung Rae Cho, MD, PhD Cardiovascular Division, Department of Internal Medicine Kangnam Sacred Heart Hospital, Hallym University Medical Center,
More informationSupplementary Online Content
Supplementary Online Content Lin Y-S, Chen Y-L, Chen T-H, et al. Comparison of Clinical Outcomes Among Patients With Atrial Fibrillation or Atrial Flutter Stratified by CHA 2 DS 2 -VASc Score. JAMA Netw
More informationAcute coronary syndromes
Acute coronary syndromes 1 Acute coronary syndromes Acute coronary syndromes results primarily from diminished myocardial blood flow secondary to an occlusive or partially occlusive coronary artery thrombus.
More informationTHROMBOPHILIA SCREENING
THROMBOPHILIA SCREENING Introduction The regulation of haemostasis Normally, when a clot occurs, it exactly occurs where it has to be and does not grow more than necessary due to the action of the haemostasis
More informationChapter. Absolute risk of venous and arterial thrombosis in HIV-infected patients and effects of combination antiretroviral therapy
Chapter Absolute risk of venous and arterial thrombosis in HIV-infected patients and effects of combination antiretroviral therapy Willem M. Lijfering Min Ki ten Kate Herman G. Sprenger Jan van der Meer
More informationWhat will we discuss today?
Autoimmune diseases What will we discuss today? Introduction to autoimmune diseases Some examples Introduction to autoimmune diseases Chronic Sometimes relapsing Progressive damage Epitope spreading more
More informationARIC Manuscript Proposal # PC Reviewed: 2/10/09 Status: A Priority: 2 SC Reviewed: Status: Priority:
ARIC Manuscript Proposal # 1475 PC Reviewed: 2/10/09 Status: A Priority: 2 SC Reviewed: Status: Priority: 1.a. Full Title: Hypertension, left ventricular hypertrophy, and risk of incident hospitalized
More informationTransient Atrial Fibrillation and Risk of Stroke after Acute Myocardial Infarction
Transient Atrial Fibrillation and Risk of Stroke after Acute Myocardial Infarction Doron Aronson MD, Gregory Telman MD, Fadel BahouthMD, Jonathan Lessick MD, DSc and Rema Bishara MD Department of Cardiology
More information